TEAD2 and cancer: To assess if TEADs binding is essential for RPC development and differentiation, we treated PSCs-derived retinal organoids with TEAD palmitoylation inhibitor MGH-CP1, that blocks TEAD2/4-YAP interaction and suppresses the expression of their target genes in cancer cell lines56.